Top

Published in:

02-03-2024 | Liposarcoma | Case Report - Radiotherapy

Spot scanning proton therapy for unresectable bulky retroperitoneal dedifferentiated liposarcoma: a case report

Authors: Koichiro Nakajima, Hiromitsu Iwata, Shuo Sudo, Toshiyuki Toshito, Kensuke Hayashi, Masaki Sunagawa, Yukihiro Yokoyama, Hiroyuki Ogino

Published in: International Cancer Conference Journal | Issue 2/2024

Abstract

The development of effective treatment strategies for unresectable retroperitoneal sarcoma is desirable. Herein, we suggest that definitive proton therapy (PT) could be a promising treatment option, regardless of the large size of the tumor. A 52-year-old man presented with a discomfort of the lower abdomen. Computed tomography revealed a retroperitoneal tumor, measuring over 20 cm in the largest dimensions, which was surrounded by the gastrointestinal (GI) tract. Biopsy revealed dedifferentiated liposarcoma. Neoadjuvant chemotherapy was ineffective, and the tumor was ultimately deemed unresectable. The patient opted to receive PT instead of continuation of chemotherapy. Spot scanning PT (SSPT) at a total dose of 60.8 Gy (relative biological effectiveness) in 16 fractions was employed. SSPT administered a dose to the tumor while successfully sparing the surrounding GI tract. He did not receive any maintenance systemic therapy after PT. The tumor gradually shrunk over more than 7 years, with no evidence of recurrence outside the irradiation field. The initial measurable tumor volume of 2925 cc decreased to 214 cc at the final follow-up, seven and a half years after PT. The patient is alive without any severe complications.

Clark MA, Fisher C, Judson I, Thomas JM (2005) Soft-tissue sarcomas in adults. N Engl J Med 353:701–711CrossRefPubMed

Almond LM, Gronchi A, Strauss D et al (2018) Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma. Eur J Surg Oncol 44:571–579CrossRefPubMed

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Soft Tissue Sarcoma. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed Nov 2023

Serizawa I, Kagei K, Kamada T et al (2009) Carbon ion radiotherapy for unresectable retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys 75:1105–1110CrossRefPubMed

Imai R, Kamada T, Araki N, Working Group for Carbon Ion Radiotherapy for Bone and Soft Tissue Sarcomas (2018) Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma. Cancer Med 7:4308–4314CrossRefPubMedPubMedCentral

Demizu Y, Fujii O, Terashima K et al (2014) Particle therapy for mucosal melanoma of the head and neck. A single-institution retrospective comparison of proton and carbon ion therapy. Strahlenther Onkol 190:186–191CrossRefPubMed

Aibe N, Demizu Y, Sulaiman NS et al (2018) Outcomes of patients with primary sacral chordoma treated with definitive proton beam therapy. Int J Radiat Oncol Biol Phys 100:972–979CrossRefPubMed

Sassa N, Yokoyama Y, Nishida Y et al (2020) Clinical characteristics and surgical outcomes of retroperitoneal tumors: a comprehensive data collection from multiple departments. Int J Clin Oncol 25:929–936CrossRefPubMed

Toshito T, Omachi C, Kibe Y et al (2016) A proton therapy system in Nagoya proton therapy center. Australas Phys Eng Sci Med 39:645–654CrossRefPubMed

10.

Nakajima K, Iwata H, Hattori Y et al (2021) Spot scanning proton therapy for sinonasal malignant tumors. Int J Part Ther 8:189–199CrossRefPubMedPubMedCentral

11.

Iwata H, Toshito T, Hayashi K et al (2019) Proton therapy for non-squamous cell carcinoma of the head and neck: planning comparison and toxicity. J Radiat Res 60:612–621CrossRefPubMedPubMedCentral

12.

Kepka L, DeLaney TF, Suit HD, Goldberg SI (2005) Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 63:852–859CrossRefPubMed

13.

Haas RL, Floot BGJ, Scholten AN et al (2021) Cellular radiosensitivity of soft tissue sarcoma. Radiat Res 196:23–30CrossRefPubMed

14.

Kamada T, Tsujii H, Tsuji H et al (2002) Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol 20:4466–4471CrossRefPubMed

15.

Cuccia F, Fiore MR, Barcellini A et al (2020) Outcome and toxicity of carbon ion radiotherapy for axial bone and soft tissue sarcomas. Anticancer Res 40:2853–2859CrossRefPubMed

16.

DeLaney TF, Chen Y-L, Baldini EH et al (2017) Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas. Adv Radiat Oncol 2:85–93CrossRefPubMedPubMedCentral

17.

Catton CN, O’Sullivan B, Kotwall C et al (1994) Outcome and prognosis in retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys 29:1005–1010CrossRefPubMed

18.

Nakashima Y, Yokoyama Y, Ogawa H et al (2023) Which modality is better to diagnose high-grade transformation in retroperitoneal liposarcoma? Comparison of computed tomography, positron emission tomography, and magnetic resonance imaging. Int J Clin Oncol 28:482–490CrossRefPubMed

19.

Mohan R, Das IJ, Ling CC (2017) Empowering intensity modulated proton therapy through physics and technology: an overview. Int J Radiat Oncol Biol Phys 99:304–316CrossRefPubMedPubMedCentral

20.

Komatsu S, Demizu Y, Sulaiman NS et al (2020) Space-making particle therapy for sarcomas derived from the abdominopelvic region. Radiother Oncol 146:194–199CrossRefPubMed

21.

Sasaki R, Demizu Y, Yamashita T et al (2019) First-in-human phase 1 study of a nonwoven fabric bioabsorbable spacer for particle therapy: space-making particle therapy (SMPT). Adv Radiat Oncol 4:729–737CrossRefPubMedPubMedCentral

Title: Spot scanning proton therapy for unresectable bulky retroperitoneal dedifferentiated liposarcoma: a case report
Authors: Koichiro Nakajima
Hiromitsu Iwata
Shuo Sudo
Toshiyuki Toshito
Kensuke Hayashi
Masaki Sunagawa
Yukihiro Yokoyama
Hiroyuki Ogino
Publication date: 02-03-2024
Publisher: Springer Nature Singapore
Keywords: Liposarcoma
Sarcoma
Soft Tissue Sarcoma
Computed Tomography
Computed Tomography
Published in: International Cancer Conference Journal / Issue 2/2024
Electronic ISSN: 2192-3183
DOI: https://doi.org/10.1007/s13691-024-00661-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2024

Coexistence of ovarian cancer and peritoneal tuberculosis: a case report

Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review

Severe hepatic sinusoidal obstruction syndrome in a patient with Wilms tumor and hereditary spherocytosis

Significant reduction in burden of metastatic disease by intermittent docetaxel therapy in a patient with castration-resistant prostate cancer

Giant retroperitoneal myolipoma mimicking liposarcoma: report of a resected case and review of the literature

Remarkable remission of symptomatic dermatomyositis after curative breast cancer surgery

Keynote webinar | Spotlight on antibody–drug conjugates in cancer